TRUE-AHF Prognostic Classification (experimental prototype)
- TRUE-AHF Prognostic Classification — explanation and clinical context
This page implements an experimental prognostic classifier inspired by common predictors used in acute heart failure (AHF) prognostic models: advanced age, low systolic blood pressure, tachycardia, elevated BUN/creatinine, hyponatremia, elevated natriuretic peptides (NT-proBNP), reduced left ventricular ejection fraction, and positive cardiac troponin. These variables have repeatedly been associated with short-term and medium-term mortality in AHF cohorts and are components of widely used tools such as the GWTG-HF and MEESSI-AHF scores. The TRUE-AHF study was a randomized trial testing ularitide in AHF and provided extensive baseline and outcome data, but there is no widely used, published “TRUE-AHF prognostic score” available to clinicians; deriving such a score would require access to the trial dataset and formal model development/validation. This prototype provides an illustrative, transparent weighting of commonly important predictors so developers can (1) replace weights with coefficients from a validated model, (2) recalibrate to local data, or (3) use the structure as a starting point when deriving a score from TRUE-AHF or another dataset.
Reference:
Packer M, et al. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF). N Engl J Med. 2017; published report of the TRUE-AHF trial.
Miró Ò, et al. Risk stratification scores for patients with acute heart failure — systematic assessments and comparisons of available tools (reviews of MEESSI, GWTG and others).
MEESSI-AHF and GWTG-HF are examples of validated AHF risk scores; consult original publications and external validations before clinical use.
Discussion
No discussions yet. Be the first to comment.